Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hang Quach

Showing results (51-60 of 119) with videos related to

Pageof 12
Sort By:
Internal Medicine Journal|August 5, 2025
Management of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: position statement of the Medical and Scientific Advisory Group of Myeloma AustraliaGeorgia McCaughan, Hayley Beer, Christian Bryant, et al.
BMC Medical Research Methodology|November 11, 2016
Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registryKrystal Bergin, Elizabeth Moore, Zoe McQuilten, et al.
Internal Medicine Journal|February 8, 2018
Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myelomaHang Quach, Simon Benson, Helen Haysom, et al.
Expert Opinion on Drug Delivery|April 13, 2026
Review of the first on-body injector (obi) for the subcutaneous delivery of an oncology drug: isatuximab in multiple myelomaEnrique M Ocio, Gurdeep Parmar, María-Victoria Mateos, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 16, 2008
In vivo tracking of dendritic cells in patients with multiple myelomaH Miles Prince, Dominic M Wall, David Ritchie, et al.
American Journal of Hematology|February 6, 2015
The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefitSimon J Harrison, Hang Quach, Emma Link, et al.
Blood Advances|May 20, 2022
Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myelomaThomas Martin, Joseph Mikhael, Roman Hajek, et al.
Annals of Hematology|August 9, 2022
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomesXavier Leleu, Thomas Martin, Katja Weisel, et al.
Internal Medicine Journal|January 8, 2026
Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory GroupShirlene Sim, Georgia McCaughan, Andrew Zannettino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2026
Efficacy and Safety of Belantamab Mafodotin with Bortezomib Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: the DREAMM-6 Arm B TrialRakesh Popat, Bradley Augustson, Paul Cannell, et al.
Pageof 12

Showing results (51-60 of 119) with videos related to

Sort By:
Pageof 12
Internal Medicine Journal|August 5, 2025
Management of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: position statement of the Medical and Scientific Advisory Group of Myeloma AustraliaGeorgia McCaughan, Hayley Beer, Christian Bryant, et al.
BMC Medical Research Methodology|November 11, 2016
Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registryKrystal Bergin, Elizabeth Moore, Zoe McQuilten, et al.
Internal Medicine Journal|February 8, 2018
Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myelomaHang Quach, Simon Benson, Helen Haysom, et al.
Expert Opinion on Drug Delivery|April 13, 2026
Review of the first on-body injector (obi) for the subcutaneous delivery of an oncology drug: isatuximab in multiple myelomaEnrique M Ocio, Gurdeep Parmar, María-Victoria Mateos, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 16, 2008
In vivo tracking of dendritic cells in patients with multiple myelomaH Miles Prince, Dominic M Wall, David Ritchie, et al.
American Journal of Hematology|February 6, 2015
The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefitSimon J Harrison, Hang Quach, Emma Link, et al.
Blood Advances|May 20, 2022
Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myelomaThomas Martin, Joseph Mikhael, Roman Hajek, et al.
Annals of Hematology|August 9, 2022
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomesXavier Leleu, Thomas Martin, Katja Weisel, et al.
Internal Medicine Journal|January 8, 2026
Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory GroupShirlene Sim, Georgia McCaughan, Andrew Zannettino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2026
Efficacy and Safety of Belantamab Mafodotin with Bortezomib Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: the DREAMM-6 Arm B TrialRakesh Popat, Bradley Augustson, Paul Cannell, et al.
Pageof 12